Lipidomics studies on macrophages - bone marrow-derived macrophages treated with 25-hydroxy-cholesterol +/- lipid-depleted media containing compactin
Introduction | Browse | DownloadMouse-over the above links for more information
Treatment details
| LM ID | Analyte | Treatment | Time(hrs) | Sample ID | Value | Units |
|---|---|---|---|---|---|---|
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 0.0 | BCD100624C002 | 17.1 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 0.5 | BCD100624C005 | 15.1 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 1.0 | BCD100624C009 | 17.5 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 2.0 | BCD100624C013 | 14.4 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 4.0 | BCD100624C017 | 21.5 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 8.0 | BCD100624C021 | 21.3 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 12.0 | BCD100624C025 | 21.8 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 24.0 | BCD100624C029 | 14.4 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 0.0 | BCD100624C001 | 12.4 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 0.5 | BCD100624C003 | 12.9 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 1.0 | BCD100624C007 | 16.6 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 2.0 | BCD100624C011 | 19 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 4.0 | BCD100624C015 | 13.7 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 8.0 | BCD100624C019 | 18 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 12.0 | BCD100624C023 | 19.8 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 24.0 | BCD100624C027 | 17.4 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 0.5 | BCD100624C006 | 16.9 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 1.0 | BCD100624C010 | 14.8 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 2.0 | BCD100624C014 | 19.4 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 4.0 | BCD100624C018 | 13.6 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 8.0 | BCD100624C022 | 19.4 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 12.0 | BCD100624C026 | 21.1 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 24.0 | BCD100624C030 | 15.1 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol | 0.5 | BCD100624C004 | 19.2 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol | 1.0 | BCD100624C008 | 23.2 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol | 2.0 | BCD100624C012 | 15.6 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol | 4.0 | BCD100624C016 | 13.6 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol | 8.0 | BCD100624C020 | 23.1 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol | 12.0 | BCD100624C024 | 19 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol | 24.0 | BCD100624C028 | 20.8 | pmol/sample |